Levels of vasopressin, somatostatin, neurotensin, vasoactive intestinal peptide, corticotrophin-releasing factor and adrenocorticotrophin in CSF were determined in lithium-treated and unmedicated euthymic bipolar patients and controls, in a search for a trait marker in affective disorder. No group differences in levels of these peptides were found. Highly significant positive correlations were found among these peptides (with the exception of neurotensin), suggesting that their presence in CSF is functionally significant, as opposed to the result of random diffusion from the interstitial space of the brain.
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Bipolar affective (manic-depressive) illness is a cyclic mood disorder of unknown aetiology, in which genetic factors play an important role in pathogenesis (for review, see Berrettini et a!, 1984). Manic depressives characteristically have cyclic episodes of markedly sad or euphoric mood, associated with other symptoms, but are well between episodes of mood disturbance. Theoretically, the underlying genetic factors, which increase one's vulnerability to develop affective illness, should be detectable independently of mood state. The study of well-state (euthymic) patients avoids the difficulty of separating state-related abnormalities (associated with acutely ill manic or depressed patients) from trait abnormalities (which may be genetic vulnerability markers). A strategy of studying euthymic patients has been delineated previously (Rieder & Gershon, 1978) . Dysregulation of the hypothalamicâ€"pituitary adrenal (HPA) axis has been observed in actively ill manic-depressive patients (Sachar eta!, 1973; Greden et a!, 1983) . Both the abnormal dexamethasone suppression test results (Greden eta!, 1983 ) and the hypercortisolaemia (Sachar et a!, 1973), seen among actively ill manic-depressive patients, are thought to disappear after remission of the depression or mama (Greden et a!, 1983). Abnormalities of pituitary adrenocorticotrophin (ACTH) response to cortico trophin-releasing factor (CRF) may accompany the dysregulation of cortisol in these patients (Gold et a!, 1984) . These observations led to the conclusion that there is some state-dependent dysfunction of the HPA axis in some patients with affective illness.
The HPA axis is regulated in part by hypothalamic neurons which release CRF, ACTH, vasopressin (AVP), somatostatin (SRIF), vasoactive intestinal peptide (VIP) or other neuropeptide transmitters and/or hormones (Axelrod & Reisine, 1984) . For these five peptides, much evidence suggests that brain is the source of the CSF levels, which are regulated independently of the plasma levels (Wood, 1982; Post eta!, 1982). In the light of the evidence that the HPA axis is regulated abnormally in the actively ill manic-depressive patient, we reasoned that evidence of a state-independent (genetic) abnormality might be found by examination of some HPA-axis-related peptides in CSF. 
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Method
All individualsparticipatingin this study were out-patients at the National Institute of Mental Health, Bethesda, Maryland. All provided informed consent. The bipolar patients and normal subjects (as well as the clinical details of the lumbar puncture) have been previously described (Berrettini eta!, l985b). Briefly, euthymic bipolar patients (who were treated solely with lithium for at least 1 month prior to study) and normal volunteersunderwenta lumbar puncture as an out-patient procedureafter 2 h of bedrest. In addition, 15of the lithium-treatedpatients discontinued lithium for at least 2 weeks to provide a second CSF sample in the unmedicated state. Thus, for these patients, paired CSF samples, on and off lithium, were obtained.
Peptide radloimmunoassay
CSF concentrations of immunoreactive human CRF were measured as previously described (Roy et a!, in press), except that unextracted CSF was used.
VIP radioimmunoassay kits were obtained from Immunoclear Corporation (Stillwater, Minnesota). VIP was determined in duplicate 0.450-nil aliquots of CSF. Recovery of added standard was 90Â°lo. Final volume was 0.650 ml.
The limit of detection was 4 pg/tube.
A volume of 0.200 ml of unextracted CSF was used to make each AVP determination, as previously described (Zerbe et a!, 1982) .
SRIF was determined on 1.00 ml of lyophilised CSF, as described previously (Patel & Reichlin, 1979 ; Rubinow et a!, 1983), and levels were corrected by indexing to chloride concentration.
NT radioimmunoassay kits were purchased from linmunoclear Corporation (Stillwater, Minnesota). NT was determinedin duplicate0.400-nil samplesof CSF collected from a l-ml fraction to which 0.020 ml of concentrated perchloricacid was added. Sampleswereadjustedto neutral pH with lO-MNaOH before assay. Recovery of added standard was 9051o, and the limit of detection was 35 pg/ml.
For the ACTH radioimmunoassay, Sep-Pak cartridges were washed with 10 ml of methanol followed by 10 ml of distilled water. Aliquots of 0.6 ml of CSF were applied to the cartridgeswhichwerethenwashedwith 10ml of distilled water. ImmunoreactiveACTH was eluted with a mixture of TEAF buffer (1Â¾formic acid, pH 3.2 with addition of triethylamine) and acetonitrile (4: 6, v/v). The eluent was lyophilised and the residue taken up in assay buffer (0.63-M Na2HPO4 and 0.l3-M Na2EDTA, pH 7.4), con taining 0.02% Na2NO2, 0.1% triton X-lOO and 250 KIU of aprotinin/mI. Therecovery ofACTH bythis procedure is 85-95%.Theantibody wasobtained fromIgGCorporation (Nashville, Tennessee, ACTH-l). Both standard and trace were ACTH139. ACTH labelled with â€˜¿ @I was prepared using the chloramine-T method (Greenwood et a!, 1963).
The specific activity was approximately 450 Ci/g. The methods of the radioimmunassay have been previously described (Orth, 1979) . The detection limit is 3â€"5 pg/mI.
Analysisof data
A general linear models procedure was used to assess the effects of age, height, weight and sex on CSF peptide levels. AUTH levels in CSF were corrected for a sex effect. Males (n = 33, x= 22.2 Â± 5.7 pg/mI) had signifi cantly higher (P<0.005) values than did females (n = 34, x= 18.4 Â± 4.7 pg/ml). No other peptide was altered significantly by age, sex, height or weight.
Group 1-tests were performed to compare euthymic bipolar patients and controls. Paired 1-tests were used to studythe effectof lithium,usingthosepatientsfrom whom paired CSF samples were obtained. Pearson correlation coefficients were calculated for the three separate groups of data (and on all individuals combined) to examine the relationships betweenthese CSF neuropeptides. Z trans formation of the correlation coefficients was done to evaluate possible significant differences in correlation coefficients between groups.
All ACTH, CRF, VIP and NT levels were measured in one assay. The coefficient of variation within an assay was less than 15% for all assays. SRIF and AVP levels were measured in two separate assays.
Results
The levels of the six neuropeptides are shown in Table I . No group differences (1-tests) or effects of lithium (paired 1-test) were found, except a trend (P= 0.05) for CSF VIP to be lower during lithium treatment.
As shown in Table II 
Discussion
The most interesting finding in this study is the significant correlations among CSF neuropeptides.
This deserves a comment on the origins of CSF neuropeptides.
Some hypothalamic neurons (that contain SRIF) have nerve endings at the wall of the third ventricle (Pollay M., 1979; Knigge et a!, 1980 where the bloodâ€"brainbarrier does not exist or by transport from the tanycyte median eminence, as well as by direct release from neurons into CSF. However, Wood's (1982) review states that peripheral sources of CSF peptides are unlikely. Thus, it seems more probable that peptides reach CSF either through random diffusion or direct neuronal release. Do the observed significant correlations favour direct release or random diffusions as the point of entry of neuropeptides into CSF? These correlations do not provide strong evidence favouring either hypothesis. However, these significant correlations are more congruous with the hypothesis that the concentrations of CRF, SRIF, AVP, VIP and ACTH in CSF are not the result of random simple diffusion from the interstitial space of the neurons of origin, because differences in number and activity of the various peptidergic neurons and their distance from the ventricular space would affect the process of random diffusion, and one would be less likely to observe significant correlations between numerous peptides (Berrettim et a!, 1985a).
One possible explanation for the correlations between SRIF, AVP, VIP, CRF and ACTH in CSF may be that they are released from neurons into CSFin response to a stimulus. From their sites of release, they may be transported to distant CNS sites where each of them may mediate some aspect of the response to that stimulus. What evidence exists for stimulus-induced changes in these CSF peptides? Koob &Britton (1984) have shown that random inescapable footshock causes a doubling in rat CSF CRF, a response which is atten uated by diazepam. CSF, ACTH and @3-endorphin levels increase several-fold following periaqueductal grey (but not internal capsule) self-stimulation for analgesia (Hosobuchi & Bloom, 1983) . These studies suggest that certain stimuli can increase CSF levels of these peptides. Shared mechanisms of release into CSF may account for these correlations.
Other possible explanations for these correlations include shared catabolism by peptidases in CSF and shared transport out of CSF, but no evidence exists to support either of these possibilities. Rubinow et a! (1985) have reported that carbamazepine, which is an effective acute and prophylactic treatment for manic-depressive illness (Okuma eta!, 1973; Post eta!, 1983) , decreases CSF SRIF levels. Because carbamazepine seems to have a therapeutic effect in the treatment of manic depressive illness which is similar to that of lithium, we hypothesised that lithium might have a similar effect on CSF SRIF. This was clearly not the case in our data. Our results support those of Rubinow eta! (1983), who reported that recovered patients did not show significantly decreased CSF SRIF levels, as was found among the acutely depressed patients.
Thus, the lower CSF SRIF level is a state-dependent marker for depression.
Given that lithium antagonises the effects of AVP (Forrest, 1979) at a post-receptor site in the kidney, we hypothesised that lithium might cause increased presynaptic release of AVP in the CNS, yielding a higher CSF AVP level. There was no effect of lithium on CSF AVP, but we cannot exclude the possibility that lithium may alter CNS AVP activity without 
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CSF neuropeplide correlations'
Gjerris et a! (1984) reported decreased CSF VIP levels in atypically depressed patients. They rated their patients atypical, using the Newcastle Rating Scale. While our patients were not rated with this scale, we believe that they are not atypical. Thus, our results in a euthymic population may be in agreement with those of Gjerris eta! (1984) , who found normal CSF VIP levels in their endogenously depressed patients.
The trend for lithium to reduce CSF VIP levels must be interpreted with caution, as it is of borderline significance. We have reported elsewhere similar results in plasma and an effect of lithium to increase the affinity of a lymphocyte VIP receptor for its ligand (Berrettini et a!, 1985b 
